2004•International Journal of Impotence ResearchRequires access

High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients

James L. Weeks, Roya Zoraghi, Alfreda Beasley, Konjeti R. Sekhar, Sharron H. Francis, Jackie D. Corbin

Open publisher page 74 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 74 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Vardenafil, Tadalafil, Sildenafil, cGMP-specific phosphodiesterase type 5, Medicine, Phosphodiesterase, Erectile dysfunction, Pharmacology

Back to paper search Browse research topics Original source

High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients — Research Paper | ScholarLens